Single-dose BNT162b2 vaccine protects against asymptomatic SARS-CoV-2 infection

The BNT162b2 mRNA COVID-19 vaccine (Pfizer-BioNTech) is being utilised internationally for mass COVID-19 vaccination. Evidence of single-dose protection against symptomatic disease has encouraged some countries to opt for delayed booster doses of BNT162b2, but the effect of this strategy on rates of...

Full description

Saved in:
Bibliographic Details
Published in:eLife
Main Authors: Jones, Nick K, Rivett, Lucy, Seaman, Shaun, Samworth, Richard J, Warne, Ben, Workman, Chris, Ferris, Mark, Wright, Jo, Quinnell, Natalie, Shaw, Ashley, Goodfellow, Ian G, Lehner, Paul J, Howes, Rob, Wright, Giles, Matheson, Nicholas J, Weekes, Michael P
Format: Artigo
Language:Inglês
Published: eLife Sciences Publications, Ltd 2021
Subjects:
Epidemiology and Global Health
Online Access:https://ncbi.nlm.nih.gov/pmc/articles/PMC8064747/
https://ncbi.nlm.nih.gov/pubmed/33830018
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.7554/eLife.68808
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items